Literature DB >> 1003870

[Alterations of bile acid metabolism during treatment with chenodeoxycholic acid. Studies of the role of the appearance of ursodeoxycholic acid in the dissolution of gallstones (author's transl)].

H Fromm, H C Erbler, A Eschler, F W Schmidt.   

Abstract

Nine patients with radiolucent stones in the gallbladder were investigated before and during treatment with chenodeoxycholic acid (CDC). During treatment the biliary composition of bile acids changed considerably. Before the ingestion of CDC,bile acids consisted predominantly of cholic acid, deoxycholic acid and CDC; lithocholic acid was present in small amounts only. In the course of treatment CDC or this bile acid together with ursodeoxycholic acid (UDC) became the major biliary bile acid. The content of CDC increased from 47.5 +/- 4.21 to 79.2 +/- 6.37 SEM %, whereas that of UDC increased from 2.7 +/- 1.15 to 13.4 +/- 6.4%. The unsulfated lithocholic acid increased slightly from 0.7 +/- 0.22 to 2.7 +/- 0.41%. The bile acid pool expanded by an average of 130%. The degree of expansion of the pool varied considerably among the different patients. The largest increase in the pool size, however, occurred in the patients with the largest content of UDC in bile. Gallstone dissolution was observed in five patients. Among these five were those patients with the highest content of UDC, Corresponding 8.6, to 29.4 and 51.7%, respectively. These findings suggest that, in addition to CDC, UDC has a cholelitholytic effect in vivo. Of interest also was the observation that the patients in whom the size of the bile acid pool increased only very little showed no dissolution of gallstones. Both the stool weight and the fecal excretion of the isotopes, after the administration of radioactively labeled bile acids, increased only slightly during the treatment with CDC. The cholelitholytically efficacious dose of 20 mg/kg/day of CDC applied in this study appears to be useful in that 94% of it was abosrbed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1003870     DOI: 10.1007/bf01469256

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  28 in total

1.  A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity.

Authors:  L L ABEL; B B LEVY; B B BRODIE; F E KENDALL
Journal:  J Biol Chem       Date:  1952-03       Impact factor: 5.157

2.  Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones.

Authors:  J L Thistle; A F Hofmann
Journal:  N Engl J Med       Date:  1973-09-27       Impact factor: 91.245

3.  Gallstone dissolution in man using chenodeoxycholic acid.

Authors:  G D Bell; B Whitney; R H Dowling
Journal:  Lancet       Date:  1972-12-09       Impact factor: 79.321

4.  Metabolism of lithocholate in healthy man. II. Enterohepatic circulation.

Authors:  A E Cowen; M G Korman; A F Hofmann; O W Cass; S B Coffin
Journal:  Gastroenterology       Date:  1975-07       Impact factor: 22.682

5.  Treatment of gallstones with chenodeoxycholic acid and phenobarbital.

Authors:  M J Coyne; G G Bonorris; A Chung; L I Goldstein; D Lahana; L J Schoenfield
Journal:  N Engl J Med       Date:  1975-03-20       Impact factor: 91.245

6.  Chenodeoxycholic acid treatment of gallstones. A follow-up report and analysis of factors influencing response to therapy.

Authors:  J H Iser; H Dowling; H Y Mok; G D Bell
Journal:  N Engl J Med       Date:  1975-08-21       Impact factor: 91.245

7.  Metabolism of lithocholate in healthy man. III. Plasma disappearance of radioactivity after intravenous injection of labeled lithocholate and its derivatives.

Authors:  A E Cowen; M G Korman; A F Hofmann; P J Thomas
Journal:  Gastroenterology       Date:  1975-07       Impact factor: 22.682

8.  Sulfation and renal excretion of bile salts in patients with cirrhosis of the liver.

Authors:  A Stiehl; D L Earnest; W H Admirant
Journal:  Gastroenterology       Date:  1975-03       Impact factor: 22.682

9.  Effect of oral chenodeoxycholic acid on bile acid kinetics and biliary lipid composition in women with cholelithiasis.

Authors:  R C Danzinger; A F Hofmann; J L Thistle; L J Schoenfield
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

10.  Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man.

Authors:  H S Mekjian; S F Phillips; A F Hofmann
Journal:  J Clin Invest       Date:  1971-08       Impact factor: 14.808

View more
  6 in total

Review 1.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

Authors:  W H Bachrach; A F Hofmann
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

2.  Study of the sensitivity and specificity of computerized tomography in the detection of calcified gallstones which appears radiolucent by conventional roentgenography.

Authors:  R P Sarva; S Farivar; H Fromm; W Poller
Journal:  Gastrointest Radiol       Date:  1981

3.  [Different effect of taurolithocholate and chenodeoxycholate on structure and function of isolated hepatocytes (author's transl)].

Authors:  J Schölmerich; K Schmidt; B Kremer; M S Becher; W Gerok
Journal:  Klin Wochenschr       Date:  1981-06-15

4.  Value of serum determinations for prediction of increased ursodeoxycholic and chenodeoxycholic levels in bile.

Authors:  F Bazzoli; H Fromm; A Roda; A K Tunuguntla; E Roda; L Barbara; P Amin
Journal:  Dig Dis Sci       Date:  1985-07       Impact factor: 3.199

5.  Relationship between serum and biliary bile acids as an indicator of chenodeoxycholic and ursodeoxycholic acid-induced hepatotoxicity in the rhesus monkey.

Authors:  F Bazzoli; A Roda; H Fromm; R P Sarva; E Roda; L Barbara
Journal:  Dig Dis Sci       Date:  1982-05       Impact factor: 3.199

6.  Gallstone dissolution treatment with a combination of chenodeoxycholic and ursodeoxycholic acids. Studies of safety, efficacy and effects on bile lithogenicity, bile acid pool, and serum lipids.

Authors:  R Roehrkasse; H Fromm; M Malavolti; A K Tunuguntla; S Ceryak
Journal:  Dig Dis Sci       Date:  1986-10       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.